病毒清除市場－全球產業規模、佔有率、趨勢、機會和預測，按應用、方法、最終用戶、地區和競爭格局分類，2020-2030年預測

全球病毒清除市場規模將從2024年的7.7334億美元成長至2030年的12.6323億美元，年複合成長率達8.52%。全球病毒清除市場涵蓋一系列專業產品和服務，旨在透過在生產過程中檢測、去除或去活化潛在的病毒污染物，確保生物製藥產品（包括治療性蛋白質、疫苗和先進療法）的病毒安全性。市場擴張的主要驅動力是全球對複雜生物製劑的需求不斷成長，以及世界各國衛生監管機構為確保產品純度和患者安全而日益嚴格的監管要求。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球病毒清除市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依應用領域（重組蛋白、血液、疫苗、其他）
  • 按方法（病毒去除法、病毒去活化法、病毒檢測法）
  • 按最終用戶（製藥和生物技術公司、合約研究組織、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美病毒清除市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲病毒清除市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區病毒清除市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲病毒清除市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美病毒清除市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球病毒清除市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Charles River Laboratories International, Inc.
• Wuxi Biologics Inc
• Eurofins Scientific SE
• Sartorius AG
• Texcell, Inc.
• Biosafety Testing Services, Inc.
• Avance Biosciences Laboratories Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Viral Clearance Market will grow from USD 773.34 Million in 2024 to USD 1263.23 Million by 2030 at a 8.52% CAGR. The global viral clearance market comprises specialized products and services designed to ensure the viral safety of biopharmaceutical products, including therapeutic proteins, vaccines, and advanced therapies, by detecting, removing, or inactivating potential viral contaminants during manufacturing. Market expansion is primarily driven by the escalating global demand for complex biologics and the increasingly stringent regulatory requirements imposed by health authorities worldwide to ensure product purity and patient safety.

Key Market Drivers

The global viral clearance market is significantly driven by the expanding biopharmaceutical and biologics pipeline, which continually introduces a greater volume and diversity of products necessitating stringent viral safety assurance. As pharmaceutical companies intensify research and development efforts, particularly in advanced therapies, the demand for robust viral clearance solutions escalates across all manufacturing stages, from cell line development to final product formulation. The inherent complexity of novel biologics, including cell and gene therapies, mandates sophisticated viral clearance strategies to meet evolving product specifications and ensure patient safety. According to J.P. Morgan, in December 2024, their '2024 Biopharma Industry Insights: Investment Trends, M&A Activity, and Market Dynamics' report indicated that biologics investment for seed and series A rounds reached $3.5 billion, underscoring the substantial financial commitment fueling this pipeline expansion and, consequently, the demand for viral clearance technologies.

Key Market Challenges

A significant challenge impeding the expansion of the global viral clearance market is the substantial investment and specialized technical expertise necessary for developing and validating effective viral clearance strategies, especially for new and varied biopharmaceutical products. This requirement places a considerable financial burden on manufacturers, particularly for smaller and emerging companies, limiting their capacity to adopt or innovate in viral clearance technologies. The complexity associated with ensuring viral safety for novel modalities, such as gene therapies or advanced protein therapeutics, demands extensive research and development resources, along with highly skilled personnel to navigate intricate regulatory pathways and perform rigorous validation studies.

Key Market Trends

The global viral clearance market is significantly influenced by the strategic shift towards integrating viral clearance assessments into the early stages of drug development. This proactive approach aims to identify and mitigate potential viral risks much sooner, ultimately streamlining the development timeline and reducing costly delays in later phases. Early consideration of viral clearance strategies also allows for the optimization of purification processes from the outset, ensuring regulatory compliance and product safety as a core component of the development paradigm rather than an afterthought. According to the Food and Drug Administration's Center for Drug Evaluation and Research, in June 2025, their "Analysis of Virus Clearance for Biotechnology Manufacturing Processes from Early to Late Phase Development" article highlighted that the risk for virus contamination in biotechnology products derived from mammalian cell lines must be evaluated from the early stages of development, underscoring this trend's regulatory and scientific importance.

Key Market Players

• Charles River Laboratories International, Inc.
• Wuxi Biologics Inc
• Eurofins Scientific SE
• Sartorius AG
• Texcell, Inc.
• Biosafety Testing Services, Inc.
• Avance Biosciences Laboratories Inc.

Report Scope:

In this report, the Global Viral Clearance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Clearance Market, By Application:

• Recombinant Proteins
• Blood
• Vaccines
• Others

Viral Clearance Market, By Method:

• Viral Removal Method
• Viral Inactivation Method
• Viral Detection Method

Viral Clearance Market, By End User:

• Pharmaceutical & Biotechnology Companies
• CROs
• Others

Viral Clearance Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Viral Clearance Market.

Available Customizations:

Global Viral Clearance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Clearance Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Recombinant Proteins, Blood, Vaccines, Others)
  • 5.2.2. By Method (Viral Removal Method, Viral Inactivation Method, Viral Detection Method)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, CROs, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Viral Clearance Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Method
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Viral Clearance Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Method
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Viral Clearance Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Method
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Viral Clearance Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Method
      • 6.3.3.2.3. By End User

7. Europe Viral Clearance Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Method
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Viral Clearance Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Method
      • 7.3.1.2.3. By End User
  • 7.3.2. France Viral Clearance Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Method
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Viral Clearance Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Method
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Viral Clearance Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Method
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Viral Clearance Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Method
      • 7.3.5.2.3. By End User

8. Asia Pacific Viral Clearance Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Method
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Viral Clearance Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Method
      • 8.3.1.2.3. By End User
  • 8.3.2. India Viral Clearance Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Method
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Viral Clearance Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Method
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Viral Clearance Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Method
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Viral Clearance Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Method
      • 8.3.5.2.3. By End User

9. Middle East & Africa Viral Clearance Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Method
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Viral Clearance Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Method
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Viral Clearance Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Method
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Viral Clearance Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Method
      • 9.3.3.2.3. By End User

10. South America Viral Clearance Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Method
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Viral Clearance Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Method
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Viral Clearance Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Method
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Viral Clearance Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Method
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Viral Clearance Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories International, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Wuxi Biologics Inc
• 15.3. Eurofins Scientific SE
• 15.4. Sartorius AG
• 15.5. Texcell, Inc.
• 15.6. Biosafety Testing Services, Inc.
• 15.7. Avance Biosciences Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer